Related Experiment Video
Updated: Jan 29, 2026
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Gamma-Carbolines Derivatives As Promising Agents for the Development of Pathogenic Therapy for Proteinopathy
V I Skvortsova1, S O Bachurin2, A A Ustyugov2
1Pirogov Russian National Research Medical University, Ostrovitianov Str., 1, Moscow, 117997, Russia.
Abstract:
Uncontrolled protein aggregation, accompanied by the formation of specific inclusions, is a major component of the pathogenesis of many common neurodegenerative diseases known as proteinopathies. The intermediate products of this aggregation are toxic to neurons and may be lethal. The development strategy of pathogenic therapy for proteinopathy is based on the design of drugs capable of both inhibiting proteinopathy progression and increasing the survival of affected neurons. The results of a decade-long research effort at leading Russian and international laboratories have demonstrated that Dimebon (Latrepirdine), as well as a number of its derivatives from a gamma-carboline group, show a strong neuroprotective effect and can modulate the course of a neurodegenerative process in both in vitro and in vivo model systems. The accumulated data indicate that gamma-carbolines are promising compounds for the development of pathogenic therapy for proteinopathies.
Insights
Gamma-carbolines, including Dimebon (Latrepirdine), show neuroprotective effects against toxic protein aggregation in neurodegenerative diseases. These compounds offer a promising therapeutic strategy for proteinopathies by inhibiting disease progression and enhancing neuronal survival.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Protein aggregation is central to neurodegenerative disease pathogenesis, forming toxic intermediates.
- These aggregates cause neuronal damage and can be lethal.
- Developing therapies for proteinopathies requires inhibiting aggregation and protecting neurons.
Purpose of the Study:
- To evaluate the neuroprotective potential of gamma-carbolines, including Dimebon (Latrepirdine).
- To explore their efficacy in modulating neurodegenerative processes.
- To assess their suitability for developing pathogenic therapies for proteinopathies.
Main Methods:
- In vitro studies of protein aggregation and neuronal survival.
- In vivo model systems for neurodegenerative diseases.
- Pharmacological evaluation of Dimebon and its gamma-carboline derivatives.
Main Results:
- Dimebon and related gamma-carbolines demonstrated significant neuroprotective effects.
- These compounds modulated the course of neurodegenerative processes in experimental models.
- Evidence supports their ability to inhibit proteinopathy progression and enhance neuronal survival.
Conclusions:
- Gamma-carbolines, including Dimebon, are effective in preclinical models of neurodegeneration.
- They represent a promising class of compounds for the pathogenic therapy of proteinopathies.
- Further development of gamma-carbolines could lead to novel treatments for neurodegenerative diseases.
Related Concept Videos
00:59Gene Therapy
01:29Subviral Agents
01:26Group Therapy
02:26Defenses Against Pathogens and Herbivores
01:31Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
01:27Air-entraining Agents